๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine373 Zhejiang University104 First Affiliated Hospital of Zhejiang University103 AstraZeneca76 Zhejiang Cancer Hospital63
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Hangzhou

1812 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
NCT07359014Relapse Multiple Myeloma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
25
Hangzhou
2025-11-01
Recruiting
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
NCT07233642Systemic Lupus Erythematosus
The Children's Hospital of Zhejiang University School of Medicine
Phase 1
18
Hangzhou
2025-11
Recruiting
Non-Invasive Fundus Retinal Detection Technology for Early Diagnosis of Parkinson's Disease
NCT07244640Parkinson's Disease (PD)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
200
Hangzhou
2025-11
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037Non-small Cell Lung Cancer (NSCLC)
AstraZeneca
Phase 3
400
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2025-10-31
Recruiting
A Digitally-Enabled System for Precision Assessment and Intervention of Disability Risk in Older Adults
NCT07508813Disability
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
238
Hangzhou
2025-10-31
Recruiting
Auricular Stimulation for Functional Dyspepsia With Insomnia: Efficacy and Mechanisms
NCT07442734Functional Dyspepsia, Insomnia, Brain and Nervous System
The First Affiliated Hospital of Zhejiang Chinese Medical University
Not applicable
176
Hangzhou
2025-10-30
Recruiting
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
NCT07219615Chronic Spontaneous Urticaria
Pfizer
Phase 2
200
Beijing, Guangzhou, Shijiazhuang, Shanghai, Tianjin, Hangzhou
2025-10-30
Recruiting
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051Bronchiectasis
GlaxoSmithKline
Phase 2
363
Beijing, Chongqing, Dongguan, Guangzhou, Guilin, Hangzhou, Huizhou, Jiangmen
2025-10-30
Recruiting
Dynamic Airway Resistance & ML: Guide Sputum Suction in Ventilated Patients
NCT07375667Mechanical Ventilation Pressure High, Ventilator-Associated Pneumonia (VAP), Respiratory Depression Neonatal
Affiliated Hospital of Nantong University
Not applicable
258
Bengbu, Beijing, Hangzhou
2025-10-30
Recruiting
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
NCT07250269Relapsed/Refractory AL Amyloidosis
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1
9
Beijing, Changchun, Guangzhou, Hangzhou, Suzhou, Wenzhou, Wuhan
2025-10-29
Not yet open
A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis
NCT07175233Atopic Dermatitis (AD)
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 2
184
Hangzhou, Shenyang
2025-10-27
Recruiting
SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer
NCT07162714Rectal Cancer, Radiation, AK112
Zhejiang Cancer Hospital
Phase 2
30
Hangzhou
2025-10-27
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Hoffmann-La Roche
Phase 3
600
Nanchang, Beijing, Changsha, Chengdu, Hangzhou, Harbin, Jinan, Nantong
2025-10-24
Recruiting
A Phase โ…ก/โ…ข Study of HRS-2129 for Postsurgical Pain Management in Abdominal Surgery
NCT07185594Postoperative Analgesia
Shandong Suncadia Medicine Co., Ltd.
Phase 2/3
360
Zhengzhou, Hangzhou
2025-10-24
Recruiting
Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients
NCT07175155Hypoxemia, Esophageal Cancer, Morbidly Obese Patients, Gastric Cancer
Zhejiang University
Not applicable
410
Beijing, Jinjiang, Hangzhou, Lishui, Taizhou
2025-10-24
Active, closed
ClinicAL outComes of IntraVascular Lithotripsy Combined With Conventional Lesion Preparation in Patients With Moderate to Severe Coronary Artery Calcification
NCT07340294Coronary Artery Calcification, Calcific Coronary Arteriosclerosis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,096
Nanchang, Shenyang, Hangzhou, Tianjin
2025-10-24
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126Non-small Cell Lung Cancer
Daiichi Sankyo
Phase 3
686
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-10-24
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173Asthma
Eli Lilly and Company
Phase 2
531
Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shanghai
2025-10-22
Active, closed
Development of a Pan-Cancer Screening Model Based on Blood Biomarkers
NCT07554157Neoplasms
Zhejiang Cancer Hospital
Observational
10,000,000
Hangzhou
2025-10-22
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
1,630
Beijing, Changchun, Changde, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan
2025-10-22
Recruiting
The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer
NCT07257653Colorectal Neoplasms, RAS, BRAF, Cetuximabฮฒ
Zhejiang University
Phase 2
70
Hangzhou
2025-10-21
Recruiting
The Efficacy of Remimazolam on Incidence of Hypoxia During Sedated Transvaginal Oocyte Retrieval: A Multicenter Randomized Controlled Trial.
NCT07335536Hypoxia, Infertility, Infertility Assisted Reproductive Technology
Diansan Su
Not applicable
400
Dongyang, Hangzhou, Lishui
2025-10-20
Active, closed
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenstrรถm Macroglobulinemia
NCT07169331Waldenstrรถm's Macroglobulinemia
BeiGene
Phase 4
16
Beijing, Guangzhou, Baoding, Yichang, Changsha, Hangzhou
2025-10-17
Recruiting
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953Alcohol Use Disorder
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei
2025-10-16
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966Alcohol Use Disorder
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Huzhou
2025-10-15
Active, closed
Fertility Decision and Outcomes in Young Women With Breast Cancer
NCT07804745Breast Cancer - Female, Fertility
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
300
Changchun, Hangzhou
2025-10-15
Recruiting
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
NCT07447570Head and Neck Cancer, Radiotherapy, Anti-PD-1/CTLA-4 Antibody
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
27
Hangzhou
2025-10-15
Recruiting
Indometacin With or Without Aggressive Intravenous Hydration to Prevent Pancreatitis After Pancreatic Extracorporeal Shock Wave Lithotripsy
NCT07202559Pancreatitis, Chronic, Pancreatitis, Acute, Pancreatic Duct Stones
Changhai Hospital
Not applicable
1,250
Baotou, Beijing, Hangzhou, Hunan, Lanzhou, Shandong, Shanghai, Yunnan
2025-10-13
Recruiting
A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors
NCT07250386NSCLC (Advanced Non-small Cell Lung Cancer), Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
48
Hangzhou
2025-10-13
Recruiting
An in Vivo CT Imaging Study of GMA-Tulip, I-gel, and LMA Supreme (GLAM-II)
NCT07196696Supraglottic Airway Device
Zhejiang Cancer Hospital
Not applicable
9
Hangzhou
2025-10-12
Recruiting
Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer
NCT07068763Rectal Cancer
Sir Run Run Shaw Hospital
Phase 2
52
Hangzhou
2025-10-09
Recruiting
Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD
NCT07385131Inflammatory Bowel Disease (IBD), CD - Crohn's Disease, UC - Ulcerative Colitis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
300
Hangzhou
2025-10-08
Recruiting
The Clinical Significance of Examining Metastatic Lymph Nodes in Individual Gastric Mesenteries in the Patients With Gastric Cancer Undergoing Gastrectomy
NCT07139418Gastric Carcinoma
Jichao Qin
Observational
400
Hangzhou
2025-10-07
Recruiting
Efficacy and Safety of iStent in Reducing Intraocular Pressure in Open-angle Glaucoma
NCT07354009Glaucoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
60
Hangzhou
2025-10-07
Recruiting
VB19055 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population
NCT07254481Hypertension
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Phase 1
86
Hangzhou, Shanghai
2025-10-05
Recruiting
Electroacupuncture Treatment for Post-stroke Cognitive Impairment
NCT07208019Post-Stroke Cognitive Impairment (PSCI)
Ruijie Ma
Not applicable
340
Hangzhou
2025-10-05
Recruiting
Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization.
NCT07329686Herpes Simplex Keratitis, Corneal Neovascularization
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1/2
100
Hangzhou
2025-10-01
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
Sanofi
Phase 3
980
Guangzhou, Huizhou, Wuxi, Chengdu, Beijing, Hangzhou, Jinan, Jingzhou
2025-10-01
Recruiting
A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia
NCT07499284Aplastic Anaemia
The First Affiliated Hospital of Soochow University
Not applicable
224
Suzhou, Xuzhou, Hangzhou
2025-10-01
Not yet open
CorVad Myocardial Infarction Complicated with Cardiogenic Shock Trial
NCT06886113Cardiogenic Shock
Shenzhen Core Medical Technology CO.,LTD.
Not applicable
269
Hangzhou
2025-10-01
Recruiting
Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver Injury
NCT07263217Cholangiocarcinoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
30
Hangzhou
2025-10-01
Not yet open
Cofrogliptin and Linagliptin as add-on Therapy to Insulin in Type 2 Diabetes
NCT07198932Type 2 Diabetes
Yanbing Li
Observational
594
Hangzhou, Baoding, Beijing, Shanghai, Xi'an
2025-10-01
Not yet open
Study on Safety and Efficacy of UCB-MNCs for Chronic Radiation Enteritis
NCT07175207Chronic Radiation Induced Intestinal Injury, Chronic Radiation Enteritis
Zhejiang Cancer Hospital
Phase EARLY_PHASE1
10
Hangzhou
2025-10-01
Active, closed
A Self-controlled Study of Bleomycin and Pingyangmycin Injection in the Treatment of Plantar Warts
NCT07197541Plantar Wart
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
200
Hangzhou
2025-10-01
Recruiting
Correlation Study of Atrophic Gastritis and Dyspepsia Symptoms
NCT07250308Functional Dyspepsia, Chronic Atrophic Gastritis (CAG)
The Third Affiliated hospital of Zhejiang Chinese Medical University
Observational
315
Hangzhou
2025-10-01
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884Urinary Incontinence,Stress
Eli Lilly and Company
Phase 3
1,000
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Lanzhou, Nanjing
2025-09-30
Recruiting
Vebreltinib for Advanced or Metastatic CCS
NCT07153887Clear Cell Sarcoma (CCS)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
30
Hangzhou
2025-09-30
Recruiting
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
NCT07022483Endometrial Cancer
Daiichi Sankyo
Phase 3
710
Beijing, Changchun, Chengdu, Hangzhou, Jinan, Linyi, Nanchang, Nanning
2025-09-30
Recruiting
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
NCT07312422Pancreatic Cancer, PD-L1, PD-1 Inhibitor, LDRT
Zhejiang Provincial People's Hospital
Phase 1/2
10
Hangzhou
2025-09-30
Recruiting
A Trial for Minimally Invasive Neurosurgery With AI-assisted Robotic Guidance for Moderate Basal Ganglia Hemorrhage (RAINBOW-MBH)
NCT06465719Basal Ganglia Hemorrhage
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
330
Hangzhou
2025-09-30
Recruiting
A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
NCT07198867Acute Myeloid Leukemia (AML), CAR-T Cell Therapy
First Affiliated Hospital of Zhejiang University
Phase 1
20
Hangzhou
2025-09-30
Recruiting
Immune Profiling of Refractory cSLE Exposed to CD3ร—CD19 BiTE
NCT07352332Childhood-onset Systemic Lupus Erythematosus
The Children's Hospital of Zhejiang University School of Medicine
Observational
6
Hangzhou
2025-09-30
Recruiting
RAINBOW-ICH Trial of AI Guided Minimally Invasive Neurosurgery for ICH
NCT07205263Basal Ganglia Hemorrhage, Intraventricular Hemorrhage, Brainstem Stroke, Intracranial Hemorrhage, Spontaneous
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,000
Hangzhou
2025-09-30
Recruiting
Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH)
NCT07198386NASH
Cascade Pharmaceuticals, Inc
Phase 2
120
Fuzhou, Xiamen, Suzhou, Shanghai, Hangzhou, Wenzhou
2025-09-30
Not yet open
A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis
NCT07150988Psoriasis
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
150
Hangzhou
2025-09-26
Recruiting
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
NCT07190196Immunoglobulin G4 Related Disease
Sanofi
Phase 3
124
Beijing, Chengdu, Hangzhou, Jiazhuang, Taiyuan, Wuhan, Yantai
2025-09-26
Recruiting
B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma
NCT07193628Refractory Glioblastoma, Recurrent Glioblastoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
14
Hangzhou
2025-09-26
Recruiting
Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD
NCT07184853Graft vs Host Disease
First Affiliated Hospital of Zhejiang University
Not applicable
122
Hangzhou
2025-09-25
Recruiting
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
NCT07080216Cervical Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
120
Hangzhou
2025-09-23
Recruiting
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged โ‰ฅ40 to โ‰ค85 Years With Chronic Obstructive Pulmonary Disease.
NCT07053423Chronic Obstructive Pulmonary Disease
Sanofi
Phase 4
218
Chengdu, Guangzhou, Hangzhou, Xiamen
2025-09-22
Recruiting
A Study of YL242 in Subjects With Advanced Solid Tumors
NCT07197827Advanced Solid Tumor
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
424
Harbin, Shanghai, Hangzhou
2025-09-22
Active, closed
Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma
NCT07247383Marginal Zone Lymphoma of Ocular Adnexal, Marginal Zone Lymphoma(MZL)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
39
Hangzhou
2025-09-19
Recruiting
New-Generation GMA Laryngeal Mask Airway Versus Conventional Inflatable Laryngeal Mask Airway
NCT07177586Supraglottic Airway Devices Position
First Affiliated Hospital of Zhejiang University
Not applicable
1,384
Hangzhou
2025-09-18
Recruiting
Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
NCT07172204Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age โ‰ฅ60
First Affiliated Hospital of Zhejiang University
Phase 2
25
Beijing, Shenzhen, Suzhou, Nanchang, Hangzhou
2025-09-16
Recruiting
Prenatal Cell-free DNA Screening in Pregnancies With Diverse Genetic Risk Profiles Utilizing Targeted and Whole-exome Sequencing
NCT07106853Genetic Disease
Women's Hospital School Of Medicine Zhejiang University
Observational
1,600
Hangzhou
2025-09-16
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
NCT07190209Chronic Obstructive Pulmonary Disease
Sanofi
Phase 3
942
Beijing, Changchun, Changsha, Chengdu, Foshan, Guangzhou, Hangzhou, Harbin
2025-09-16
Not yet open
Correlation Between COVID-19 and Radiation Pneumonitis in Breast Cancer
NCT07188116Breast Cancer, Radiation Pneumonia, COVID-19
Zhejiang Hospital
Observational
200
Hangzhou
2025-09-15
Recruiting
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim
Phase 3
400
Beijing, Chengdu, Guangzhou, Hangzhou, Luoyang, Macau, Nanchang, Shanghai
2025-09-13
Recruiting
Accelerated Intermittent Theta Burst Stimulation (AiTBS)on Neuropathic Pain
NCT07148388Neuropathic Pain, Nociceptive Pain
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
120
Hangzhou
2025-09-12
Recruiting
Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical Resection
NCT07368803Biliary Malignant Tumors
Yifan Wang
Phase 1/2
20
Hangzhou
2025-09-11
Recruiting
A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection
NCT07495215Hepatocellular Carcinoma (HCC)
Yinghua Xu
Phase 1/2
20
Hangzhou
2025-09-11
Recruiting
Real-Time Dynamic Imaging Study of Normal Pharyngolaryngeal Structures During Barium Swallow (GLAM-III)
NCT07264322Barium Meal Examination
Zhejiang Cancer Hospital
Observational
3
Hangzhou
2025-09-10
Recruiting
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
NCT06855771Carcinoma, Non-Small-Cell Lung
Bristol-Myers Squibb
Phase 2
182
Beijing, Xiamen, Nanning, Nanchang, Jinan, Linyi, Hangzhou, Linhai
2025-09-09
Recruiting
PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS
NCT07761533Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome)
Chaser Therapeutics, Inc.
Phase 1/2
29
Hangzhou
2025-09-08
Recruiting
A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis
NCT07129382Plaque Psoriasis
Chipscreen Biosciences, Ltd.
Phase 1/2
220
Beijing, Chengde, Shijiazhuang, Shiyan, Jinan, Taiyuan, Xiโ€™an, Hangzhou
2025-09-08
Not yet open
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT07159906Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
First Affiliated Hospital of Zhejiang University
Phase 1/2
62
Hangzhou
2025-09-08
Recruiting
Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia
NCT07144020Acute Myeloid Leukemia
Zhejiang University
Phase EARLY_PHASE1
50
Hangzhou
2025-09-05
Recruiting
Microneedle Intra-Arterial Injection for Retinal Artery Occlusion
NCT07151755Central Retinal Artery Occlusion
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
24
Hangzhou
2025-09-01
Not yet open
The Resistant Starch Intervention for Cognitive Enhancement
NCT07152483Cognitive Impairment, Diet Interventions, Cognitive Decline, Genetic Risk Factors
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
70
Hangzhou
2025-09-01
Active, closed
Evaluation of the Safety and Efficacy of a Wideband Electric Pulse Tumor Ablation System for Malignant Pulmonary Nodules
NCT07638228Malignant Pulmonary Nodules, Lung Cancer
Sir Run Run Shaw Hospital
Not applicable
5
Hangzhou
2025-09-01
Recruiting
Efficacy of Electroacupuncture for Acute Herpes Zoster-Associated Pain and Biomarker Evaluation
NCT07515885Acute Herpes Zoster
Dexiong Han
Not applicable
228
Hangzhou
2025-09-01
Recruiting
Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC
NCT07303023Nasopharyngeal Carcinoma (NPC)
Fudan University
Phase 3
462
Shanghai, Hangzhou, Chengdu, Chongqing
2025-09-01
Recruiting
Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer
NCT06561308Endometrioid Endometrial Cancer
Women's Hospital School Of Medicine Zhejiang University
Phase 2
39
Hangzhou
2025-09-01
Recruiting
AI-assisted Diagnosis of Malignant Brain Tumors
NCT07198256Gliomas, Brain Metastases, Adult, Lymphoma, Brain Tumor Adult
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
3,000
Hangzhou
2025-09-01
Not yet open
Endoscopic Pancreatic Duct Stent Placement Versus Conventional Approach in the Treatment of Early Phase Acute Pancreatitis
NCT07093996Acute Pancreatitis (AP)
Almazov National Medical Research Centre
Not applicable
200
Hangzhou
2025-09-01
Recruiting
Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma
NCT07207278Signet Ring Cell Carcinoma of the Lung
First People's Hospital of Hangzhou
Observational
39
Hangzhou
2025-09-01
Not yet open
Investigating the Therapeutic Efficacy of All-trans Retinoic Acid in Autism Spectrum Disorder Patients With 15q11-13 Duplication Syndrome
NCT07079696Dup15q Syndrome, Autism Spectrum Disorder, Therapy, All-trans Retinoic Acid
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
90
Hangzhou
2025-09-01
Recruiting
Clinical Evaluation of With or Without Internal Limiting Membrane Peeling for Idiopathic Epiretinal Membrane Surgery: A Randomized Controlled Trial
NCT07142785Idiopathic Epiretinal Membranes
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
96
Hangzhou
2025-09-01
Recruiting
Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
NCT07184450Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis, Systemic Sclerosis (SSc), Primary Sjogren's Syndrome
Chongqing Precision Biotech Co., Ltd
Phase 1
11
Hangzhou
2025-09-01
Not yet open
Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients
NCT06796660Renal Insufficiency, Chronic
Liu Zhanghong
Phase EARLY_PHASE1
70
Hangzhou, Wenzhou
2025-09-01
Recruiting
Clinical Study of the Pulsed Electric Field Ablation System in Chronic Obstructive Pulmonary Disease
NCT07068438Chronic Bronchitis, COPD (Chronic Obstructive Pulmonary Disease)
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
210
Hefei, Beijing, Changzhou, Suzhou, Wuxi, Xuzhou, Nanchang, Hangzhou
2025-09-01
Recruiting
Deep Learning CAD Screening on Chest CT
NCT07181512Coronary Artery Disease, Coronary Artery Stenosis Stent
Yifan Guo
Observational
200
Hangzhou, Ningbo
2025-09-01
Not yet open
Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis
NCT07054736Atopic Dermatitis
Zhejiang Kanova Biopharmaceutical Co., LTD
Phase 2
120
Hangzhou
2025-08-31
Recruiting
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.
NCT07377175Smallpox, Cowpox, Monkeypox, Poxvirus Infection
China National Biotec Group Company Limited
Phase 1
76
Hangzhou
2025-08-28
Recruiting
A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors
NCT07123129Advanced Malignancy
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
200
Beijing, Hangzhou
2025-08-28
Recruiting
A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
NCT07110571Gastric Cancer, Gastroesophageal-junction Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
200
Shijiazhuang, Hangzhou
2025-08-28
Recruiting
A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence
NCT07087314Nephrotic Syndrome in Children
Mao Jianhua
Phase 2
30
Hangzhou
2025-08-25
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
NCT07181473Lung Cancer (NSCLC), Prostate Cancer, Esophageal Cancer, Solid Tumor Malignancies
Phrontline Biopharma
Phase 1
200
Zhengzhou, Wuhan, Hangzhou, Shanghai
2025-08-25
Recruiting
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
NCT07058077Heterozygous Familial Hypercholesterolemia (HeFH)
Merck Sharp & Dohme LLC
Phase 2/3
153
Beijing, Guangzhou, Shanghai, Hangzhou
2025-08-21
Recruiting
Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)
NCT07183878Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndromes, High-Risk Myelodysplastic Syndromes
First Affiliated Hospital of Zhejiang University
Not applicable
138
Hangzhou
2025-08-20
Rows per page Showing 501–600 of 1812
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou?page=6

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,812 of those studies with a site in Hangzhou.

How many clinical trials are recruiting in Hangzhou?

1,096 of the 1,812 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 300 have not yet opened recruitment, 372 are active but closed to new participants, and 44 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.